The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC).
 
Katia Khoury
No Relationships to Disclose
 
Rebecca Feldman
Employment - Caris Life Sciences
 
Paula Raffin Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Consulting or Advisory Role - HERON; Immunonet BioSciences; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Puma Biotechnology
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377
 
Arielle Lutterman Heeke
No Relationships to Disclose
 
Zoran Gatalica
Employment - Caris Life Sciences
 
Yvonne Veloso
Employment - Caris Life Sciences
 
Gregory A. Vidal
Consulting or Advisory Role - Lilly; Pfizer
Speakers' Bureau - AstraZeneca; Pfizer
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Lilly; Pfizer; Puma Biotechnology; Tesaro
 
Lee S. Schwartzberg
Stock and Other Ownership Interests - Vector Oncology
Honoraria - Amgen; E.R. Squibb Sons, LLC; Genentech; Helsinn Healthcare; NanoString Technologies; Napo Pharmaceuticals; Novartis; Pfizer; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Caris Life Sciences; E.R. Squibb Sons, LLC; Genentech; Genomic Health; Helsinn Therapeutics; Lilly; Novartis; Pfizer; Roche; Spectrum Pharmaceuticals; Tesaro; Vector Oncology
Research Funding - Amgen (Inst); Bayer Health (Inst); E.R. Squibb Sons, LLC (Inst); E.R. Squibb Sons, LLC (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Tesaro (Inst)
 
Sandra M. Swain
Honoraria - Novartis
Consulting or Advisory Role - Cardinal Health; Daiichi Sankyo; Genentech/Roche; Genentech/Roche; Genomic Health; Inivata; Lilly; Pieris Pharmaceuticals; Tocagen
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Caris Centers of Excellence; Daiichi Sankyo; Genentech/Roche; Inivata; Lilly; NanoString Technologies
Other Relationship - AstraZeneca; Roche
 
Claudine Isaacs
Honoraria - AstraZeneca; Genentech/Roche; Pfizer
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Medivation; NanoString Technologies; Novartis; Pfizer; Syndax
Speakers' Bureau - AstraZeneca; Genentech; Pfizer
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - McGraw Hill Publishing; UpToDate
 
Filipa Lynce
Research Funding - AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences (Inst); Chugai Pharma USA (Inst); Immunomedics (Inst); Inivata (Inst); Jounce Therapeutics; Pfizer; Regeneron (Inst); Tesaro (Inst)